Generic Aristada Availability
Last updated on Apr 10, 2025.
Aristada is a brand name of aripiprazole, approved by the FDA in the following formulation(s):
ARISTADA (aripiprazole lauroxil - suspension, extended release;intramuscular)
-
Manufacturer: ALKERMES INC
Approval date: October 5, 2015
Strength(s): 441MG/1.6ML (275.63MG/ML) [RLD], 662MG/2.4ML (275.83MG/ML) [RLD], 882MG/3.2ML (275.63MG/ML) [RLD] -
Manufacturer: ALKERMES INC
Approval date: June 5, 2017
Strength(s): 1064MG/3.9ML (272.82MG/ML) [RLD]
Is there a generic version of Aristada available?
No. There is currently no therapeutically equivalent version of Aristada available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aristada. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Heterocyclic compounds for the treatment of neurological and psychological disorders
Patent 10,112,903
Issued: October 30, 2018
Inventor(s): Remenar Julius F. & Blumberg Laura Cook & Zeidan Tarek A.
Assignee(s): ALKERMES PHARMA IRELAND LIMITEDLactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.
Patent expiration dates:
- June 24, 2030✓✓
- June 24, 2030
-
Pharmaceutical compositions comprising sorbitan esters
Patent 10,226,458
Issued: March 12, 2019
Inventor(s): Perry Jason M. & Deaver Daniel R. & Hickey Magali B. & Remenar Julius F. & Vandiver Jennifer
Assignee(s): ALKERMES PHARMA IRELAND LIMITEDThe present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.
Patent expiration dates:
- March 19, 2032✓
- March 19, 2032
-
Aripiprazole formulations having increased injection speeds
Patent 10,238,651
Issued: March 26, 2019
Inventor(s): Hickey Magali B. & Vandiver Jennifer
Assignee(s): ALKERMES PHARMA IRELAND LIMITEDThe present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.
Patent expiration dates:
- March 19, 2035✓
- March 19, 2035
-
Aripiprazole formulations having increased injection speeds
Patent 10,813,928
Issued: October 27, 2020
Inventor(s): Hickey Magali B. & Vandiver Jennifer
Assignee(s): ALKERMES PHARMA IRELAND LIMITEDThe present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.
Patent expiration dates:
- March 19, 2035✓
- March 19, 2035✓
- March 19, 2035
-
Pharmaceutical compositions having improved storage stability
Patent 11,097,006
Issued: August 24, 2021
Inventor(s): Perry Jason M. & Deaver Daniel R. & Hickey Magali B. & Remenar Julius F. & Vandiver Jennifer & Palmieri & Jr. Michael J. & Pan Zhengzheng
Assignee(s): ALKERMES PHARMA IRELAND LIMITEDThe present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent
Patent expiration dates:
- October 24, 2033✓✓
- October 24, 2033
-
Aripiprazole dosing strategy
Patent 11,273,158
Issued: March 15, 2022
Inventor(s): von Moltke Lisa L. & Weiden Peter J. & Hard Marjie L.
Assignee(s): Alkermes Pharma Ireland LimitedThe present invention relates to methods of treating schizophrenia using a combination of aripiprazole, aripiprazole lauroxil, and a nanoparticle dispersion of aripiprazole lauroxil.
Patent expiration dates:
- April 6, 2039✓
- April 6, 2039
-
Aripiprazole formulations having increased injection speeds
Patent 11,406,632
Issued: August 9, 2022
Inventor(s): Hickey; Magali B. et al.
Assignee(s): ALKERMES PHARMA IRELAND LIMITED (Dublin, IE)The present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.
Patent expiration dates:
- March 19, 2035✓
- March 19, 2035
-
Aripiprazole dosing strategy
Patent 12,251,381
Issued: March 18, 2025
Inventor(s): von Moltke; Lisa L. et al.
Assignee(s): Alkermes Pharma Ireland Limited (Dublin, IE)The present invention relates to methods of treating schizophrenia using a combination of aripiprazole, aripiprazole lauroxil, and a nanoparticle dispersion of aripiprazole lauroxil.
Patent expiration dates:
- April 9, 2039✓
- April 6, 2039✓
- April 9, 2039
-
Heterocyclic compounds for the treatment of neurological and psychological disorders
Patent 8,431,576
Issued: April 30, 2013
Inventor(s): Remenar Julius F. & Blumberg Laura Cook & Zeidan Tarek A.
Assignee(s): Alkermes Pharma Ireland LimitedLactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.
Patent expiration dates:
- October 26, 2030✓
- October 26, 2030
-
Heterocyclic compounds for the treatment of neurological and psychological disorders
Patent 8,796,276
Issued: August 5, 2014
Inventor(s): Remenar Julius F. & Blumberg Laura Cook & Zeidan Tarek A.
Assignee(s): Alkermes Pharma Ireland LimitedLactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.
Patent expiration dates:
- June 24, 2030✓
- June 24, 2030
-
Pharmaceutical compositions comprising sorbitan esters
Patent 9,034,867
Issued: May 19, 2015
Inventor(s): Perry Jason M. & Deaver Daniel R. & Hickey Magall B. & Remenar Julius F. & Vandiver Jennifer
Assignee(s): ALKERMES PHARMA IRELAND LIMITEDThe present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.
Patent expiration dates:
- November 7, 2032✓✓
- November 7, 2032
-
Pharmaceutical compositions having improved storage stability
Patent 9,193,685
Issued: November 24, 2015
Inventor(s): Perry Jason M. & Deaver Daniel R. & Hickey Magali B. & Remenar Julius F. & Vandiver Jennifer & Palmieri & Jr. Michael J. & Pan Zhengzheng
Assignee(s): ALKERMES PHARMA IRELAND LIMITEDThe present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent
Patent expiration dates:
- October 24, 2033✓✓
- October 24, 2033
-
Aripiprazole formulations having increased injection speeds
Patent 9,452,131
Issued: September 27, 2016
Inventor(s): Hickey Magali B. & Vandiver Jennifer
Assignee(s): ALKERMES PHARMA IRELAND LIMITEDThe present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.
Patent expiration dates:
- March 19, 2035✓
- March 19, 2035
-
Aripiprazole formulations having increased injection speeds
Patent 9,526,726
Issued: December 27, 2016
Inventor(s): Hickey Magali B. & Vandiver Jennifer
Assignee(s): ALKERMES PHARMA IRELAND LIMITEDThe present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.
Patent expiration dates:
- March 19, 2035✓
- March 19, 2035
More about Aristada (aripiprazole)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (17)
- Drug images
- Latest FDA alerts (5)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: atypical antipsychotics
- Breastfeeding
- En español
Patient resources
Other brands
Abilify, Abilify Maintena, Abilify Asimtufii, Abilify MyCite, ... +2 more
Professional resources
Other brands
Abilify, Abilify Maintena, Abilify Asimtufii, Abilify MyCite, ... +2 more
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.